Tango Therapeutics Shares Fall 14% After Pancreatic Cancer Study Results
An ongoing study found vopimetostat was not well tolerated at a certain dose level. Tango Therapeutics shares fell 14% to $24.13 on Friday.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.